High coexpression of CCL2 and CX3CL1 is gender‐specifically associated with good prognosis in soft tissue sarcoma patients. Issue 9 (4th April 2014)

• Record Type: Journal Article
• Authors: Kehlen, Astrid; Greither, Thomas; Wach, Sven; Nolte, Elke; Kappler, Matthias; Bache, Matthias; Holzhausen, Hans‐Jürgen; Lautenschläger, Christine; Göbel, Steffen; Würl, Peter; Immel, Uta‐Dorothee; Agaimy, Abbas; Wullich, Bernd; Taubert, Helge
• Is Part Of: International journal of cancer. Volume 135:Issue 9(2014:Nov. 01)
• Page Start: 2096
• Page End: 2106
• Publication Date: 2014-04-04
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.28867
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Chemokines are involved in both the negative and positive regulation of inflammatory processes, angiogenesis and cancer/cancer stem cell proliferation as well as the chemoattraction of tumor cells to metastatic sites. The aim of this study was to measure the mRNA expression levels of three chemokines, <italic>CCL2</italic>, <italic>CCL7</italic> and <italic>CX3CL1</italic>, in soft tissue sarcomas (STSs) and to assess the correlations between these levels as well as their correlations with clinicopathological data and the disease‐specific survival of STS patients. The mRNA levels of <italic>CCL2</italic>, <italic>CCL7</italic> and <italic>CX3CL1</italic> were analyzed in tumor tissues from 126 STS patients using qPCR. Low mRNA expression of <italic>CCL2</italic> and <italic>CX3CL1</italic> was significantly correlated with a worse prognosis (RR = 1.98; <italic>p</italic> = 0.019 and RR = 2.10; <italic>p</italic> = 0.014; multivariate Cox's regression analysis). A combined low expression of <italic>CCL2</italic> and <italic>CX3CL1</italic> was associated with a significantly increased risk of tumor‐related death as compared to patients with high expression levels of both chemokines (RR = 3.08; <italic>p</italic> = 0.003). A gender‐specific multivariate analysis revealed that female STS patients with low <italic>CX3CL1</italic> mRNA expression had a 3.46‐fold increased risk of death (<italic>p</italic> = 0.004). Low expression of both <italic>CCL2</italic> and <italic>CX3CL1</italic> mRNAs resulted in an additive 5.37‐fold increased risk of tumor‐related death (<italic>p</italic> = 0.003) as compared to those with high expression of both parameters in female patients. In conclusion, this is the first study to show a significant correlation between combined low expression of <italic>CCL2</italic> and <italic>CX3CL1</italic> and a poor prognosis for STS patients, particularly in female patients.</p> </abstract>